Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
International recommendations for plasma Epstein-Barr virus DNA measurement in nasopharyngeal carcinoma in resource-constrained settings: lessons from the COVID-19 pandemic.
Lee VH, Adham M, Ben Kridis W, Bossi P, Chen MY, Chitapanarux I, Gregoire V, Hao SP, Ho C, Ho GF, Kannarunimit D, Kwong DL, Lam KO, Lam WKJ, Le QT, Lee AW, Lee NY, Leung TW, Licitra L, Lim DW, Lin JC, Loh KS, Lou PJ, Machiels JP, Mai HQ, Mesía R, Ng WT, Ngan RK, Tay JK, Tsang RK, Tong CC, Wang HM, Wee JT. Lee VH, et al. Among authors: leung tw. Lancet Oncol. 2022 Dec;23(12):e544-e551. doi: 10.1016/S1470-2045(22)00505-8. Lancet Oncol. 2022. PMID: 36455583 Free PMC article. Review.
Dose-response relationship of nasopharyngeal carcinoma above conventional tumoricidal level: a study by the Hong Kong nasopharyngeal carcinoma study group (HKNPCSG).
Teo PM, Leung SF, Tung SY, Zee B, Sham JS, Lee AW, Lau WH, Kwan WH, Leung TW, Chua D, Sze WM, Au JS, Yu KH, O SK, Kwong D, Yau TK, Law SC, Sze WK, Au G, Chan AT. Teo PM, et al. Among authors: leung sf, leung tw. Radiother Oncol. 2006 Apr;79(1):27-33. doi: 10.1016/j.radonc.2006.03.012. Epub 2006 Apr 19. Radiother Oncol. 2006. PMID: 16626829
A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma.
Lee AW, Tung SY, Chan AT, Chappell R, Fu YT, Lu TX, Tan T, Chua DT, O'Sullivan B, Tung R, Ng WT, Leung TW, Leung SF, Yau S, Zhao C, Tan EH, Au GK, Siu L, Fung KK, Lau WH. Lee AW, et al. Among authors: leung tw, leung sf. Radiother Oncol. 2011 Jan;98(1):15-22. doi: 10.1016/j.radonc.2010.09.023. Radiother Oncol. 2011. PMID: 20971520 Clinical Trial.
Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH, Tin VP, Choy TS, Lam KO, Choi CW, Chung LP, Tsang JW, Ho PP, Leung DK, Ma ES, Liu J, Shek TW, Kwong DL, Leung TW, Wong MP. Lee VH, et al. Among authors: leung tw, leung dk. J Thorac Oncol. 2013 Sep;8(9):1148-55. doi: 10.1097/JTO.0b013e31829f684a. J Thorac Oncol. 2013. PMID: 23945384 Free article.
Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma.
Lee VH, Leung DK, Luk MY, Tong CC, Law MW, Ng SC, Wong KK, Poon RT, Kwong DL, Leung TW. Lee VH, et al. Among authors: leung tw, leung dk. Onco Targets Ther. 2015 Nov 20;8:3457-64. doi: 10.2147/OTT.S92473. eCollection 2015. Onco Targets Ther. 2015. PMID: 26640386 Free PMC article.
Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL. Lee VH, et al. Among authors: leung tw, leung dk. BMC Cancer. 2016 Feb 24;16:147. doi: 10.1186/s12885-016-2201-9. BMC Cancer. 2016. PMID: 26911310 Free PMC article. Clinical Trial.
438 results